Rituximab versus cyclophosphamide for ANCA-associated vasculitis

John H. Stone, Peter A. Merkel, Robert Spiera, Philip Seo, Carol A. Langford, Gary S. Hoffman, Cees G.M. Kallenberg, E. William St Clair, Anthony Turkiewicz, Nadia K. Tchao, Lisa Webber, Linna Ding, Lourdes P. Sejismundo, Kathleen Mieras, David Weitzenkamp, David Ikle, Vicki Seyfert-Margolis, Mark Mueller, Paul Brunetta, Nancy B. AllenFernando C. Fervenza, Duvuru Geetha, Karina A. Keogh, Eugene Y. Kissin, Paul A. Monach, Tobias Peikert, Coen Stegeman, Steven R. Ytterberg, Ulrich Specks

Research output: Contribution to journalArticlepeer-review

1558 Scopus citations


BACKGROUND: Cyclophosphamide and glucocorticoids have been the cornerstone of remission-induction therapy for severe antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis for 40 years. Uncontrolled studies suggest that rituximab is effective and may be safer than a cyclophosphamide-based regimen. METHODS: We conducted a multicenter, randomized, double-blind, double-dummy, noninferiority trial of rituximab (375 mg per square meter of body-surface area per week for 4 weeks) as compared with cyclophosphamide (2 mg per kilogram of body weight per day) for remission induction. Glucocorticoids were tapered off; the primary end point was remission of disease without the use of prednisone at 6 months. RESULTS: Nine centers enrolled 197 ANCA-positive patients with either Wegener's granulomatosis or microscopic polyangiitis. Baseline disease activity, organ involvement, and the proportion of patients with relapsing disease were similar in the two treatment groups. Sixty-three patients in the rituximab group (64%) reached the primary end point, as compared with 52 patients in the control group (53%), a result that met the criterion for noninferiority (P<0.001). The rituximab-based regimen was more efficacious than the cyclophosphamide-based regimen for inducing remission of relapsing disease; 34 of 51 patients in the rituximab group (67%) as compared with 21 of 50 patients in the control group (42%) reached the primary end point (P=0.01). Rituximab was also as effective as cyclophosphamide in the treatment of patients with major renal disease or alveolar hemorrhage. There were no significant differences between the treatment groups with respect to rates of adverse events. CONCLUSIONS: Rituximab therapy was not inferior to daily cyclophosphamide treatment for induction of remission in severe ANCA-associated vasculitis and may be superior in relapsing disease. (Funded by the National Institutes of Allergy and Infectious Diseases, Genentech, and Biogen; ClinicalTrials.gov number, NCT00104299.)

Original languageEnglish (US)
Pages (from-to)221-232
Number of pages12
JournalNew England Journal of Medicine
Issue number3
StatePublished - Jul 15 2010

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'Rituximab versus cyclophosphamide for ANCA-associated vasculitis'. Together they form a unique fingerprint.

Cite this